KURA ONCOLOGY
At Kura Oncology, They are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how they treat cancer. They now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that ar... e safer and more effective for patients with particular cancers. They are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Their development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.
KURA ONCOLOGY
Industry:
Biopharma Biotechnology Genetics Health Care Medical
Founded:
2014-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.kuraoncology.com
Total Employee:
101+
Status:
Active
Contact:
858-500-8835
Email Addresses:
[email protected]
Total Funding:
791.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Tag Manager WordPress Content Delivery Network Font Awesome Domain Not Resolving
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Private Equity Round - Kura Oncology
Partner Fund Management
Partner Fund Management investment in Private Equity Round - Kura Oncology
EcoR1 Capital
EcoR1 Capital investment in Private Equity Round - Kura Oncology
Tavistock Life Sciences
Tavistock Life Sciences investment in Private Equity Round - Kura Oncology
Nextech Invest
Nextech Invest investment in Private Equity Round - Kura Oncology
ARCH Venture Partners
ARCH Venture Partners investment in Private Equity Round - Kura Oncology
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Private Equity Round - Kura Oncology
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-18 | Kura Oncology Appoints Teresa Bair as Chief Legal Officer |
Official Site Inspections
http://www.kuraoncology.com Semrush global rank: 2.02 M Semrush visits lastest month: 10.42 K
Unable to get host informations!!!
More informations about "Kura Oncology"
About Us - Kura Oncology
Sep 22, 2022 Previously, he was Executive Vice President & Head of Research, Development, and Medical Affairs at ImmunoGen. Prior to ImmunoGen, he was the Chief Medical Officer and …See details»
Kura Oncology - Crunchbase Company Profile & Funding
Organization. Kura Oncology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; Phone Number 858-500-8835; At Kura …See details»
Careers - Kura Oncology
Across the organization, Kura’s employees operate with excellence and a patient-first mindset to realize the promise of the company’s mission to develop novel precision medicines for patients …See details»
Kura Oncology, Inc. | LinkedIn
Kura Oncology, Inc. | 22,015 followers on LinkedIn. Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. | Kura Oncology is a ...See details»
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of …
Sep 17, 2024 “On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of …See details»
Kura Oncology CEO and Key Executive Team | Craft.co
Kura Oncology's Chief Operating Officer is Kathleen Ford. Other executives include Troy Wilson, President, Chief Executive Officer, Director and Chairman; Stephen Dale, Chief Medical …See details»
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of ...
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision …See details»
Kura Oncology and Kyowa Kirin Announce Global Strategic …
Nov 20, 2024 – Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right …See details»
Kura Oncology Announces Transition of Chief Medical Officer
For additional information about Kura, please visit the Company’s website at www.kuraoncology.com. Forward-Looking Statements This news release contains certain …See details»
Kura Oncology, Inc. (KURA) Stock Price, News, Quote
Find the latest Kura Oncology, Inc. (KURA) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Newsroom - Kura Oncology
Kura Oncology, Inc. 12730 High Bluff Drive, Suite 400 San Diego, CA 92130 (858) 500-8800. Kura Oncology, Inc. 2 Seaport Lane, Suite 8A Boston, MA 02210See details»
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of ...
Sep 18, 2024 For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn. Forward-Looking Statements This news release contains …See details»
Press Release - Kura Oncology, Inc.
Apr 22, 2024 [email protected]. Media: Alexandra Weingarten Associate Director, Corporate Communications & Investor Relations (858) 500-8822 …See details»
Kura Oncology Receives Breakthrough Therapy ... - Markets Insider
Apr 22, 2024 Kura is on track to complete the registration-directed trial of ziftomenib in R/R NPM1-mutant AML by mid-2024. Ziftomenib is also being evaluated in combination with …See details»
The History and Culture of Kura
Mar 21, 2023 Kura Oncology, Inc. 12730 High Bluff Drive, Suite 400 San Diego, CA 92130 (858) 500-8800. Kura Oncology, Inc. 2 Seaport Lane, Suite 8A Boston, MA 02210See details»
Kura Oncology Receives Breakthrough Therapy Designation for …
Apr 22, 2024 Kura Oncology, Inc. – Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of …See details»
Kura Oncology Announces Positive Results from - GlobeNewswire
Oct 17, 2023 [email protected] 1 HRAS variant allele frequency ≥ 20% and treated with at least one dose of tipifarnib 2 One low VAF patient (< 20% VAF) was a responder to …See details»
Our Approach - Kura Oncology
With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. …See details»
Pipeline - Kura Oncology
KO-2806. KO-2806 is a potent next-generation FTI designed to improve upon potency, pharmacokinetic and physicochemical properties of earlier FTI drug candidates and address …See details»